Novo Nordisk A/S
F:NOVA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novo Nordisk A/S
F:NOVA
|
DK |
|
N
|
Novo Nordisk A/S
XMUN:NOVA
|
DK |
Intrinsic Value
The intrinsic value of 
Novo Nordisk A/S (NOVA) under the Base Case is 45.69 EUR per share.
Compared with the current market price of 35.62 EUR, the stock appears
Undervalued by 22% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Novo Nordisk A/S Does
Novo Nordisk is a global drug company best known for medicines that treat diabetes and obesity. It also sells treatments for rare blood disorders, growth hormone deficiency, and other chronic diseases. The company does not make consumer products; it develops prescription medicines that doctors prescribe and patients use over long periods.
- Headquarters
- Denmark DK
- Employees
- 47 792
- IPO date
- May 17, 1974
Novo Nordisk A/S has a wide economic moat
Legal protection for key medicines prevents rivals from selling direct copies in major markets, helping Novo Nordisk keep profits from its diabetes and obesity treatments. Competitors must develop different medicines and prove they work rather than simply copy its protected products.
Read the full moat analysis
Revenue & Expenses Breakdown
Novo Nordisk A/S
Earnings Waterfall
Novo Nordisk A/S
The intrinsic value for Novo Nordisk A/S (NOVA) under the Base Case is 45.69 EUR.
Compared with the current market price of 35.62 EUR, the stock appears Undervalued by 22% .